Table 1.

Summary of mouse phenotypes

	CD19Cre/+	CD19Cre/+KrasG12D/+	CD19Cre/+Ink4a/Arf L/+	CD19Cre/+KrasG12D/+Ink4a/Arf L/+
Premalignant
Number of mice	3	3	3	3
Spleen weight, mg	127 ± 12	194 ± 6**	173 ± 12**	213 ± 6**†*
Spleen cells × 107	10.6 ± 0.6	14.0 ± 0.8**	12.6 ± 1.2 (ns)	16.5 ± 1.0**†*
Malignant
No. of mice	10	20	20	26
Lymphoma type	None(10 of 10)	Low-grade B lymphoma(8 of 20)	Pre-B-ALL(12 of 20)	Pre-B-ALL(26 of 26)

Engineered mice of the indicated genotypes were analyzed before overt malignancy (premalignant; 8 weeks of age) or following development of leukemia/lymphoma (malignant). For spleen weight and cell number, the standard deviation is provided.

ns, not significant.

P values were calculated relative to CD19^Cre/+ or CD19^Cre/+Ink4a/Arf^L/+ (†) using Welch’s t test. *P ≤ .05; **P ≤ .01.